Literature DB >> 26961365

Long-term cost effectiveness of cardiac secondary prevention in primary care in the Republic of Ireland and Northern Ireland.

Paddy Gillespie1, Edel Murphy2, Susan M Smith3, Margaret E Cupples4, Molly Byrne5, Andrew W Murphy6.   

Abstract

While cardiac secondary prevention in primary care is established practice, little is known about its long-term cost effectiveness. This study examines the cost effectiveness of a secondary prevention intervention in primary care in the Republic of Ireland and Northern Ireland over 6 years. An economic evaluation, based on a cluster randomised controlled trial of 903 patients with heart disease, was conducted 4.5 years after the intervention ceased to be delivered. Patients originally randomised to the control received usual practice while those randomised to the intervention received a tailored care package over the 1.5-year delivery period. Data on healthcare costs and quality adjusted life expectancy were used to undertake incremental cost utility analysis. Multilevel regression was used to estimate mean cost effectiveness and uncertainty was examined using cost effectiveness acceptability curves. At 6 years, there was a divergence in the results across jurisdictions. While the probability of the intervention being cost effective in the Republic of Ireland was 0.434, 0.232, 0.180, 0.150, 0.115 and 0.098 at selected threshold values of €5000, €15,000, €20,000, €25,000, €35,000 and €45,000, respectively, all equivalent probabilities for Northern Ireland equalled 1.000. Our findings suggest that the intervention in its current format is likely to be more cost effective than usual general practice care in Northern Ireland, but this is not the case in the Republic of Ireland.

Entities:  

Keywords:  Coronary heart disease; Cost effectiveness analysis; General practice; Secondary prevention

Mesh:

Year:  2016        PMID: 26961365     DOI: 10.1007/s10198-016-0777-2

Source DB:  PubMed          Journal:  Eur J Health Econ        ISSN: 1618-7598


  23 in total

1.  CONSORT statement: extension to cluster randomised trials.

Authors:  Marion K Campbell; Diana R Elbourne; Douglas G Altman
Journal:  BMJ       Date:  2004-03-20

2.  Methods for covariate adjustment in cost-effectiveness analysis that use cluster randomised trials.

Authors:  Manuel Gomes; Richard Grieve; Richard Nixon; Edmond S-W Ng; James Carpenter; Simon G Thompson
Journal:  Health Econ       Date:  2012-03-28       Impact factor: 3.046

3.  A guide to cost-effectiveness acceptability curves.

Authors:  Elisabeth Fenwick; Sarah Byford
Journal:  Br J Psychiatry       Date:  2005-08       Impact factor: 9.319

4.  Cost effectiveness of personal health education in primary care for people with angina in the greater Belfast area of Northern Ireland.

Authors:  C O'Neill; C Normand; M Cupples; A McKnight
Journal:  J Epidemiol Community Health       Date:  1996-10       Impact factor: 3.710

5.  Multiple imputation methods for handling missing data in cost-effectiveness analyses that use data from hierarchical studies: an application to cluster randomized trials.

Authors:  Manuel Gomes; Karla Díaz-Ordaz; Richard Grieve; Michael G Kenward
Journal:  Med Decis Making       Date:  2013-08-01       Impact factor: 2.583

6.  Measuring the quality of well-being in cystic fibrosis and lung transplantation. The importance of the area under the curve.

Authors:  D M Orenstein; R M Kaplan
Journal:  Chest       Date:  1991-10       Impact factor: 9.410

7.  Cost-effectiveness acceptability curves--facts, fallacies and frequently asked questions.

Authors:  Elisabeth Fenwick; Bernie J O'Brien; Andrew Briggs
Journal:  Health Econ       Date:  2004-05       Impact factor: 3.046

8.  Translating policy into practice: a case study in the secondary prevention of coronary heart disease.

Authors:  Lindsay Prior; Joanne Wilson; Michael Donnelly; Andrew W Murphy; Susan M Smith; Mary Byrne; Molly Byrne; Margaret E Cupples
Journal:  Health Expect       Date:  2011-12-12       Impact factor: 3.377

9.  The SPHERE Study. Secondary prevention of heart disease in general practice: protocol of a randomised controlled trial of tailored practice and patient care plans with parallel qualitative, economic and policy analyses. [ISRCTN24081411].

Authors:  Andrew W Murphy; Margaret E Cupples; Susan M Smith; Molly Byrne; Claire Leathem; Mary C Byrne
Journal:  Curr Control Trials Cardiovasc Med       Date:  2005-07-29

10.  Effect of tailored practice and patient care plans on secondary prevention of heart disease in general practice: cluster randomised controlled trial.

Authors:  A W Murphy; M E Cupples; S M Smith; M Byrne; M C Byrne; J Newell
Journal:  BMJ       Date:  2009-10-29
View more
  3 in total

1.  Potential Cost Savings for the Healthcare System by Physical Activity in Different Chronic Diseases: A Pilot Study in the Veneto Region of Italy.

Authors:  Sara Ortolan; Daniel Neunhaeuserer; Giulia Quinto; Barbara Barra; Anna Centanini; Francesca Battista; Marco Vecchiato; Valentina De Marchi; Martina Celidoni; Vincenzo Rebba; Andrea Ermolao
Journal:  Int J Environ Res Public Health       Date:  2022-06-16       Impact factor: 4.614

2.  Long-term outcomes after revascularization and medical therapy in premature coronary artery disease for cost-effectiveness study: A systematic review protocol.

Authors:  Farbod Ebadi Fard Azar; Ali Aboutorabi; Mohammad Afrouzi; Marjan Hajahmadi; Sanaz Karpasand
Journal:  J Educ Health Promot       Date:  2021-08-31

3.  The MultimorbiditY COllaborative Medication Review And DEcision Making (MyComrade) study: a protocol for a cross-border pilot cluster randomised controlled trial.

Authors:  Lisa Hynes; Andrew W Murphy; Nigel Hart; Collette Kirwan; Sarah Mulligan; Claire Leathem; Laura McQuillan; Marina Maxwell; Emma Carr; Scott Walkin; Caroline McCarthy; Colin Bradley; Molly Byrne; Susan M Smith; Carmel Hughes; Maura Corry; Patricia M Kearney; Geraldine McCarthy; Margaret Cupples; Paddy Gillespie; John Newell; Liam Glynn; Alberto Alvarez-Iglesias; Carol Sinnott
Journal:  Pilot Feasibility Stud       Date:  2022-03-28
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.